ReviewInternational journal of molecular sciences2021
Sarcopenic Obesity in Liver Cirrhosis: Possible Mechanism and Clinical Impact.
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Effects of exercise interventions on inflammatory biomarker levels in older adults with frailty and/or sarcopenia: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- New-onset and relapsed liver diseases following COVID-19 vaccination: a systematic review.BMC gastroenterology · 2022Pooled it
- Geriatric Nutritional Risk Index and risks of all-cause, cardiovascular, and diabetes-related mortality in adults with obesity: A nationally representative cohort study.American heart journal plus : cardiology research and practice · 2026Article
- Sarcopenic obesity in cirrhosis: prognostic value and future perspectives.Nutrition & metabolism · 2026Review
- Metabolic Dysfunction-Associated Steatotic Liver Disease and Sarcopenia: Review of Literature.Journal of clinical medicine · 2026Review
- Prognostic impact of low muscle mass and visceral adiposity in patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt: a retrospective cohort study.Frontiers in nutrition · 2026Article
- A simple score of sarcopenic obesity predicts all-cause mortality in patients with cirrhosis.Frontiers in medicine · 2026Article
- Platelet bioenergetics correlate with skeletal muscle respiration in a murine model of type II diabetes.Frontiers in molecular biosciences · 2025Article
- Hepatocellular Carcinoma Among Patients With Metabolic Dysfunction Associated Steatotic Liver Disease.Gastro hep advances · 2025Article
- Gut-liver-muscle axis: linking gut microbiota dysbiosis to malnutrition and sarcopenia in liver disease.Frontiers in medicine · 2025Review
- Article
- Liver at crossroads: unraveling the links between obesity, chronic liver diseases, and the mysterious obesity paradox.Clinical and experimental medicine · 2024Review
- Sarcopenic obesity in patients awaiting liver transplant: Unique challenges for nutritional recommendations.World journal of transplantation · 2024Review
- Clinical Overview of Sarcopenia, Frailty, and Malnutrition in Patients With Liver Cirrhosis.Gastroenterology research · 2024Review
- Pathophysiological-Based Nutritional Interventions in Cirrhotic Patients with Sarcopenic Obesity: A State-of-the-Art Narrative Review.Nutrients · 2024Review
- Landscape and research trends of sarcopenic obesity research: A bibliometric analysis.Heliyon · 2024Review
- Forgettable in the care of liver cirrhosis: the unseen culprits of progression from bad to worse.Przeglad gastroenterologiczny · 2024Review
- What Does Sarcopenia Have to Do with Nonalcoholic Fatty Liver Disease?Life (Basel, Switzerland) · 2023Review
- Article
- Multimodal assessment of non-alcoholic fatty liver disease with transmission-reflection optoacoustic ultrasound.Theranostics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The picture of chronic liver diseases (CLDs) has changed considerably in recent years. One of them is the increase of non-alcoholic fatty liver disease. More and more CLD patients, even those with liver cirrhosis (LC), tend to be presenting with obesity these days. The annual rate of muscle loss increases with worsening liver reserve, and thus LC patients are more likely to complicate with sarcopenia. LC is also characterized by protein-energy malnutrition (PEM). Since the PEM in LC can be invariable, the patients probably present with sarcopenic obesity (Sa-O), which involves both sarcopenia and obesity. Currently, there is no mention of Sa-O in the guidelines; however, the rapidly increasing prevalence and poorer clinical consequences of Sa-O are recognized as an important public health problem, and the diagnostic value of Sa-O is expected to increase in the future. Sa-O involves a complex interplay of physiological mechanisms, including increased inflammatory cytokines, oxidative stress, insulin resistance, hormonal disorders, and decline of physical activity. The pathogenesis of Sa-O in LC is diverse, with a lot of perturbations in the muscle-liver-adipose tissue axis. Here, we overview the current knowledge of Sa-O, especially focusing on LC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.